Peli Filip (Bucharest)

Manuela Lupeanu

Peli Filip (Bucharest)
Lawyer ( Senior Associate)

Manuela Lupeanu is currently working as a Senior Associate at Peli Filip. She attended the University of Bucharest and the University of Paris I Pantheon Sorbonne - French - Romanian Law College of European Studies. In 2006 she obtained a Master Degree in European Union Law at the University of Strasbourg 3 Robert Schuman (Strasbourg, France). Before joining Peli Filip, Manuela has previously worked within the competition law team of a large Romanian law firm, where she was involved in antitrust issues, state aid related activities and merger notifications to the Competition Council. Highlights include assisting an important pharmaceutical distributor during the final stage of the Competition Council investigation, assisting a large cosmetics producer during a Competition Council investigation or assisting a large international steel company on state aid issues. Manuela Lupeanu is a member of Bucharest Bar.

Linked authors

Peli Filip (Bucharest)
Peli Filip (Bucharest)

Articles

6922 Bulletin

Carmen Peli, Manuela Lupeanu The Romanian Competition Council fines for client sharing agreements 14 administrators of mandatory pensions funds, applying for the first time both Art. 101(1) TFUE and national mirror provision (Pension Funds administrators case)

923

On 16 September 2010 the Romanian Competition Council (the “Council”) published Decision n° 39/07.09.2010 sanctioning almost all the players in the Romanian market for private administration of mandatory pensions funds (14 out of 18 players active on the market) for a client sharing cartel (the (...)

Carmen Peli, Manuela Lupeanu The Romanian Competition Authority fines EUR 22.6 M distributors and manufacturer for sharing insulin portfolio (Eli Lilly / A&A Medical / Mediplus Exim / Relad Pharma)

4160

The Romanian Competition Council (the “Council”) continued in 2008 the series of decisions dedicated to the malfunctioning of the Romanian pharmaceutical market, by sanctioning through its decision 15/2008 (i) the insulin producer Eli Lilly Export SA and three of its distributors, A&A Medical (...)

Send a message